Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Regulatory News (VRP)

  • There is currently no data for VRP

Final Results

3 May 2006 10:34

ISIS Resources PLC03 May 2006 ISIS RESOURCES PLC ("Isis" or the "Company") Final results for the period ended 31 December 2005 Chairman's statement The Company was incorporated on 24 February 2005 and its ordinary shares wereadmitted to AIM on 31 March 2005 in conjunction with a fundraising ofapproximately £1 million. During the period since admission to AIM, the Directors have reviewed a numberof natural resource opportunities and, in each case, concluded that theproposition did not offer an appropriate level of return for the risk to beassumed. Consequently, the Directors reviewed the Company's investment strategyand widened the range of potential investments. On 31 March 2006, the Directors announced that the company's shares had beensuspended from trading on AIM in accordance with the Guidance Note to Rule 8 ofthe AIM Rules. The Directors further announced that they are in discussions inrelation to the acquisition of a drug discovery company which is focused on thediscovery and development of new therapeutic drugs for the treatment of rhinitisand other chronic respiratory and inflammatory diseases. The acquisition wouldbe classified as a reverse takeover under the AIM Rules and, as such, would besubject to the approval of shareholders. In conjunction with the acquisition, the Directors announced that the Companyintends to undertake a placing of ordinary shares through its nominated adviserand broker, Westhouse Securities LLP. The Directors expect that an AIMadmission document in connection with the acquisition will be published aroundthe end of May 2006. Craig Burton Executive Chairman Contact Details: Craig Burton 00 61 8 9324 1177 Isis Resources Plc Tim Feather 020 7601 6100 Westhouse Securities LLP INCOME STATEMENT FOR THE PERIOD ENDED 31 DECEMBER 2005 Notes £ Revenue - Cost of sales - __________Gross profit - Administration expenses (11,380) Other operating income 3,899 __________ Operating profit/(loss) (7,481) Investment income 33,448 __________ Profit before taxation 25,967 Taxation - __________ Profit for the period 25,967 ========= Earnings per ordinary share 1 0.06p __________ Diluted earnings per ordinary share 1 0.05p __________ BALANCE SHEET AS AT 31 DECEMBER 2005 £ ASSETS Current assets Trade and other receivables 8,918 Cash and cash equivalents 982,408 __________ 991,326 __________ Total assets 991,326 ========= EQUITY AND LIABILITIES Share capital 50,200 Share premium account 903,412 Retained losses 25,967 __________ Total equity 979,579 __________ Current liabilities Trade and other payables 11,747 __________ Total liabilities 11,747 __________ Total equity and liabilities 991,326 ========= CASH FLOW STATEMENT FOR THE PERIOD ENDED 31 DECEMBER 2005 £ Net cash inflows from operating activities 2,173 __________ Investing activities Interest received 26,623 __________ 26,623 __________ Financing activities Net proceeds from issue of ordinary share capital 953,612 __________ 953,612 __________ Net increase in cash and cash equivalents 982,408 Cash and cash equivalents at the beginning of the period - __________ Cash and cash equivalents at the end of the period 982,408 ========= Notes to the preliminary results for the period ended 31 December 2005 1. Earnings per share Basic earnings per share of 0.06p is calculated by dividing the profit for theperiod by the weighted average number of ordinary shares in issue of 44,754,194. Diluted earnings per share of 0.05p is calculated by dividing the profit for theperiod by the diluted weighted average number of ordinary shares of 54,611,613,being the number of ordinary shares in issue and allowing for the exercise ofoptions outstanding. 2. Publication of non-statutory accounts The financial information set out in this preliminary announcement does notconstitute statutory accounts as defined in section 240 of the Companies Act1985. The summarised consolidated balance sheet at 31 December 2005 and thesummarised consolidated profit and loss account, summarised consolidatedcashflow statement and associated notes for the year then ended have beenextracted from the Group's 2005 statutory financial statements upon which theauditors' opinion is unqualified and does not contain any statement undersection 237 of the Companies Act 1985. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Jan 202011:00 pmGNWVerona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
7th Jan 20207:00 amGNWVerona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations
28th Nov 201910:25 amGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
27th Nov 20197:00 amGNWVerona Pharma plc: Grant of Options to PDMR
18th Nov 20197:00 amGNWVerona Pharma plc: PDMR Dealing – Purchase by Chairman
14th Nov 20197:00 amGNWVerona Pharma plc: PDMR Dealing – Purchase by Chairman
13th Nov 20197:00 amGNWVerona Pharma to Present at Jefferies 2019 London Healthcare Conference
11th Nov 20197:00 amGNWVerona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
5th Nov 20197:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019
29th Oct 20197:00 amGNWVerona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update
17th Oct 20197:00 amGNWVerona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
15th Oct 20197:00 amGNWVerona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
19th Sep 20197:00 amGNWVerona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
9th Sep 20192:33 pmGNWHolding(s) in Company TR-1: Standard form for notification of major holdings
3rd Sep 20197:00 amGNWVerona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
9th Aug 20199:35 amGNWVerona Pharma plc: PDMR Dealing
6th Aug 20197:00 amGNWVerona Pharma plc: Operational Update and Financial Results for the Three and Six Months Ended June 30, 2019
5th Aug 20197:00 amGNWVerona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
30th Jul 20197:00 amGNWVerona Pharma to Announce Financial Results for Second Quarter Ended June 30, 2019 and Provide Clinical Development Update
24th Jul 20197:00 amGNWVerona Pharma to Attend BTIG Biotechnology Conference 2019 and Present at 2019 Wedbush PacGrow Healthcare Conference
25th Jun 20197:00 amGNWVerona Pharma Strengthens its Clinical Team Ahead of Phase 3 Development of Ensifentrine
4th Jun 20197:00 amGNWVerona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD
30th May 20197:00 amGNWVerona Pharma to Present at Jefferies 2019 Global Healthcare Conference
29th May 201911:07 amRNSPDMR Dealing
20th May 20193:15 pmGNWVerona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
7th May 201912:51 pmGNWResult of AGM
7th May 20197:00 amGNWVerona Pharma Initiates Additional Phase 2b Clinical Trial with Nebulized Ensifentrine to Inform Dose Selection for Phase 3 Trials
7th May 20197:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
2nd May 201912:00 pmGNWVerona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference
1st May 20197:00 amGNWVerona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update
1st May 20197:00 amGNWVerona Pharma plc ("Verona" or the "Company") Appointment of Nominated Adviser and UK Broker
25th Apr 201912:07 pmGNWVerona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019
4th Apr 20197:00 amGNWGrant of Options and RSUs and PDMR Dealings
26th Mar 20197:00 amGNWVerona Pharma to Present at H.C. Wainwright Global Life Sciences Conference
25th Mar 20197:00 amGNWPDMR Dealing
22nd Mar 20194:00 pmGNW2018 Annual Report and Accounts and Notice of AGM 
11th Mar 20199:48 amGNWPDMR Dealing
7th Mar 20198:14 amGNWPDMR Dealing
5th Mar 20199:48 amGNWPDMR Dealing
4th Mar 20197:00 amGNWVerona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD
28th Feb 20197:00 amGNWVerona Pharma to Present at Cowen and Company 39th Annual Health Care Conference
26th Feb 20197:00 amGNWVerona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update
20th Feb 20197:00 amGNWVerona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update
4th Feb 20197:00 amGNWVerona Pharma to Present at Upcoming Investor Conferences
14th Jan 20197:00 amGNWVerona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment
9th Jan 20191:00 pmGNWVerona Pharma Receives WHO Approval for “ensifentrine” as Recommended INN for RPL554
17th Dec 20185:20 pmGNWVerona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
17th Dec 20187:00 amGNWVerona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD
6th Nov 20187:00 amGNWVerona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018
31st Oct 20187:00 amGNWVerona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.